Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

William G. Wierda, Paolo Ghia, Nicole Lamanna et al.|The Lancet Haematology|2024

Cited by 37